GLP-1 Receptor Agonists in Patients with Diverticulosis
GLP-1 receptor agonists are safe to prescribe in patients with diverticulosis, as there are no contraindications or evidence suggesting increased risk of diverticular complications. Diverticulosis itself does not appear on any contraindication list for these medications, and the primary gastrointestinal effects—delayed gastric emptying and upper GI symptoms—do not affect colonic diverticula 1, 2, 3.
Safety Profile and Gastrointestinal Effects
The gastrointestinal adverse effects of GLP-1 receptor agonists are predominantly upper GI in nature and do not involve the colon where diverticula are located. The most common side effects include nausea (17–44%), vomiting (7–25%), diarrhea (12–32%), constipation (10–23%), and abdominal pain (predominantly upper abdominal) 1, 4, 5. These effects are dose-dependent, typically mild-to-moderate, and decrease over time, usually resolving within 4–8 weeks 1, 4.
The mechanism of GLP-1 receptor agonists involves delaying gastric emptying by inhibiting gastric peristalsis and increasing pyloric tone via vagal pathways 2, 6. This gastric-slowing effect does not directly impact colonic motility or increase intra-colonic pressure in a manner that would predispose to diverticular perforation or diverticulitis 2, 3.
Absolute Contraindications (Unrelated to Diverticulosis)
The only absolute contraindications to GLP-1 receptor agonists are a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2), based on animal studies showing thyroid C-cell tumors 1, 3. Diverticulosis is not among these contraindications.
Practical Prescribing Considerations
When prescribing GLP-1 receptor agonists to patients with diverticulosis:
Initiate with slow dose titration to minimize gastrointestinal side effects, starting at the lowest available dose and escalating every 4 weeks 1, 7.
Monitor for gastrointestinal symptoms during the first 4–8 weeks, particularly nausea, vomiting, and abdominal pain, which are common but typically transient 1, 4, 5.
Distinguish between medication-related upper abdominal discomfort and potential diverticulitis. GLP-1-related abdominal pain is typically diffuse upper abdominal discomfort associated with early satiety, bloating, and nausea 1. In contrast, diverticulitis presents with left lower quadrant pain, fever, and localized tenderness—symptoms unrelated to GLP-1 therapy 3.
Educate patients that gastrointestinal side effects are expected, dose-dependent, and usually resolve within 4–8 weeks of reaching a stable dose 1, 4.
Common Pitfalls to Avoid
Do not withhold GLP-1 receptor agonists based solely on the presence of diverticulosis, as there is no evidence-based reason to do so 1, 2, 3.
Do not confuse upper GI symptoms from GLP-1 therapy with diverticular disease, which affects the colon and presents with distinct lower abdominal symptoms 1, 3.
Do not overlook serious complications such as pancreatitis (persistent severe abdominal pain) or gallbladder disease (right upper quadrant pain with fever), which require immediate discontinuation of the medication 1, 2.
Special Considerations for Colonoscopy
If a patient with diverticulosis requires colonoscopy with sedation while on a GLP-1 receptor agonist, the medication must be stopped due to aspiration risk from delayed gastric emptying, not because of diverticulosis 3. Recommended holding periods are 3 weeks for semaglutide, tirzepatide, and dulaglutide, and 3–4 days for liraglutide 3. For colonoscopy without sedation, the GLP-1 receptor agonist can be continued without interruption 3.